All findings

Every finding from every agent that has run. Decisions made here count at the current step: the document is approved, so findings are final.

Export all to PPT

Mapping & Synthesis phase (15 cards)

New since your last review

Diagnosis Code Footprint

The supplied evidence identifies ICD-10-CM Acute Lymphoblastic Leukemia diagnosis codes within the C91.0 family, including active disease, remission, and relapse states. Legacy ICD-9-CM concepts for active disease, remission, relapse, and personal history of lymphoid leukemia are also provided.

Diagnostic

Ready | 6 sources |includes web evidence

What this means

Claims-based ALL cohorts can be stratified by disease state using explicit remission and relapse diagnosis coding. Longitudinal line-of-therapy analyses may use diagnosis-state transitions between C91.00, C91.01, and C91.02 as monitoring signals.

Worth checking: Confirm whether C91.00 should be interpreted as both active disease and failed remission in the intended analytic framework.

Sources

NLM Clinical Tables (ICD-10-CM) CMS ICD-10-CM Release Files NLM Clinical Tables (ICD-9-CM) NLM Clinical Tables (HCPCS)

Code system	Code	Description	Use
ICD-10-CM	C91.00	Acute lymphoblastic leukemia not having achieved remission	Active disease or failed-remission ALL identification
ICD-10-CM	C91.01	Acute lymphoblastic leukemia, in remission	Remission-state ALL monitoring
ICD-10-CM	C91.02	Acute lymphoblastic leukemia, in relapse	Relapse-state ALL monitoring
ICD-9-CM	20400	Acute lymphoid leukemia, without mention of having achieved remission	Legacy active disease identification
ICD-9-CM	20401	Acute lymphoid leukemia, in remission	Legacy remission-state identification
ICD-9-CM	20402	Acute lymphoid leukemia, in relapse	Legacy relapse-state identification
ICD-9-CM	V1061	Personal history of lymphoid leukemia	Legacy personal-history identification

Diagnostic Procedure & Lab Codes

The supplied materials identify HCPCS, CPT, and LOINC concepts related to bone marrow evaluation, flow cytometry, and FISH cytogenetic testing relevant to ALL diagnostic workup and monitoring. Genomic targets referenced in the evidence include BCR/ABL1, KMT2A, ETV6/RUNX1, CRLF2, ABL1, ABL2, PDGFRB, PBX1;TCF3, and CDKN2A.

Diagnostic

Ready | 4 sources |includes web evidence

What this means

Procedure and laboratory utilization can provide observable diagnostic and disease-monitoring signals in claims-linked datasets when direct treatment-intent coding is incomplete. Repeated bone marrow, flow cytometry, and FISH testing may support longitudinal assessment of disease activity and follow-up.

Worth checking: Check whether additional CPT hematopathology or molecular pathology codes are required for the intended claims algorithm.

Sources

NLM Clinical Tables (HCPCS) NLM Clinical Tables (LOINC) CMS ICD-10-CM Release Files Open Web (Supplementary)

Category	Code system	Example codes	Purpose
Bone marrow aspiration and biopsy	HCPCS	G0364	Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service
Bone marrow biopsy device	HCPCS	C1830	Powered bone marrow biopsy needle
Bone marrow pathology reporting	LOINC	33721-2; 66119-9; 48807-2	Bone marrow pathology biopsy report and bone marrow aspiration report concepts
Flow cytometry laboratory assessment	LOINC	33719-6; 61126-9; 107079-6; 61123-6; 30364-4; 101147-7; 104548-3; 54226-6	Flow cytometry study, blast-cell assessment, and lymphocyte/leukocyte quantification
FISH cytogenetic testing	CPT	88237; 88275; 88271	FISH testing for diagnostic, prognostic, and follow-up evaluation

Code System Crosswalk

The supplied evidence aligns legacy ICD-9-CM acute lymphoid leukemia concepts with ICD-10-CM Acute Lymphoblastic Leukemia remission-state concepts. ICD-11 stem or extension mappings were not provided.

Diagnostic

Ready | 6 sources |includes web evidence

What this means

Legacy claims data using ICD-9-CM can be aligned to ICD-10-CM remission-state ALL concepts using the supplied wording-based mappings. International harmonization and molecular subtype representation remain limited because ICD-11 mappings were not identified.

Worth checking: Verify whether wording-based ICD-9 to ICD-10 alignment is sufficient without formal GEM or CMS crosswalk references.

Sources

NLM Clinical Tables (ICD-9-CM) NLM Clinical Tables (ICD-10-CM) CMS ICD-10-CM Release Files NLM Clinical Tables (HCPCS)

ICD-9-CM	ICD-10-CM	ICD-11	Description
20400	C91.00	Not provided	Acute lymphoid/leukoblastic leukemia not having achieved remission or without mention of remission
20401	C91.01	Not provided	Acute lymphoid/leukoblastic leukemia, in remission
20402	C91.02	Not provided	Acute lymphoid/leukoblastic leukemia, in relapse
V1061	Not provided	Not provided	Personal history of lymphoid leukemia

Claims Observability Limits

The supplied evidence documents multiple claims observability gaps affecting ALL cohort construction and line-of-therapy inference. Key limitations include incomplete procedure coverage, absent ICD-11 subtype coding, and lack of clinical-trial participation markers.

Diagnostic

Ready | 6 sources |includes web evidence

The supplied evidence does not provide ICD-11 stem or extension codes for molecular or lineage-specific ALL subtype representation.
The supplied documents do not provide coding conventions for suspected-versus-confirmed diagnoses, secondary malignancy involvement, or ICD-10-CM personal-history Z85 mappings.
Procedure-code coverage is incomplete because the evidence set does not include comprehensive CPT, HCPCS, or ICD-10-PCS coding for leukapheresis, stem-cell transplantation workflows, conditioning regi
Clinical-trial participation indicators, including HCPCS modifiers Q0 and Q1, investigational service indicators, and revenue-code markers, were not identified in the supplied materials.
Many monitoring signals in ALL claims analytics may therefore require proxy inference from diagnosis-state transitions, laboratory utilization, or repeated bone marrow and flow-cytometry testing rathe

What this means

Claims-based ALL analytics using this evidence set will rely heavily on proxy signals rather than direct treatment coding. Missing subtype, procedure, and trial-participation visibility may limit cohort specificity and treatment-pathway reconstruction.

Worth checking: Assess whether supplemental coding sources are needed to support transplant, CAR-T, and chemotherapy administration observability.

Sources

NLM Clinical Tables (ICD-10-CM) CMS ICD-10-CM Release Files NLM Clinical Tables (ICD-9-CM) NLM Clinical Tables (HCPCS)

Line-of-Therapy Rules

The supplied evidence provides therapy-specific cycle timing and interruption rules for BLINCYTO and BESPONSA that may support line advancement, continuation, and discontinuation logic in ALL claims sequencing. The document does not provide a complete standardized U.S. claims-based line-of-therapy algorithm.

Logic

Ready | 9 sources |includes web evidence

BLINCYTO induction or consolidation consists of 28 days of continuous intravenous infusion followed by a 14-day treatment-free interval.
BLINCYTO continued therapy consists of 28 days of continuous intravenous infusion followed by a 56-day treatment-free interval.
BLINCYTO interruptions due to adverse reactions that are 7 days or less may continue within the same cycle.
BLINCYTO interruptions longer than 7 days require starting a new cycle.
BESPONSA Cycle 1 is 3 weeks in duration and may be extended to 4 weeks for complete remission, complete remission with incomplete hematologic recovery, or toxicity recovery.
BESPONSA interruptions greater than 28 days may require consideration of permanent discontinuation, and HSCT-directed treatment is recommended for 2 cycles in patients proceeding to hematopoietic stem

What this means

These timing and interruption thresholds can support cycle segmentation and treatment continuation logic for relapsed or refractory ALL therapies in claims analyses. Additional governance rules are still required for regimen aggregation, maintenance grouping, and cross-agent line advancement definitions.

Worth checking: Expert review should confirm whether interruption thresholds are operationalized as line breaks or cycle restarts in the target claims framework.

Sources

FDA Drug Labeling (openFDA) DailyMed NLM Clinical Tables (HCPCS) ESMO

Regimen Library

The evidence identifies several ALL-related therapy constructs and comparator regimens, including subpopulation-specific relapsed/refractory and maintenance settings, but does not provide a comprehensive standardized U.S. regimen library across all treatment phases.

Logic

Ready | 6 sources |includes web evidence

What this means

The evidence supports construction of partial regimen libraries tied to specific ALL subpopulations and treatment phases. Analysts would still need external governance for regimen aliases, induction versus consolidation categorization, and maintenance normalization.

Worth checking: Expert review should verify whether comparator regimens should be classified as distinct lines or pooled chemotherapy backbones.

Sources

ESMO FDA Drug Labeling (openFDA) DailyMed FDA Purple Book

Regimen	Setting / phase	Components	Population
BESPONSA-based therapy	Relapsed or refractory setting	Inotuzumab ozogamicin	Adult and pediatric patients with relapsed or refractory CD22-positive B-cell precursor ALL
BLINCYTO-based therapy	Relapsed or refractory setting	Blinatumomab	Patients with relapsed or refractory B-cell precursor ALL
FLAG comparator regimen	Investigator-choice chemotherapy comparator regimen	Fludarabine + cytarabine + granulocyte colony-stimulating factor	Patients with relapsed/refractory ALL
MXN/Ara-C comparator regimen	Investigator-choice chemotherapy comparator regimen	Mitoxantrone + cytarabine	Patients with relapsed/refractory ALL
HIDAC comparator regimen	Investigator-choice chemotherapy comparator regimen	High-dose cytarabine	Patients with relapsed/refractory ALL
Methotrexate-containing maintenance regimen	Maintenance therapy	Methotrexate as part of combination chemotherapy maintenance regimen	Patients with ALL
Mercaptopurine-containing maintenance regimen	Maintenance therapy	Mercaptopurine as part of combination chemotherapy maintenance regimen	Patients with ALL
Pediatric-inspired asparaginase-containing regimens	Frontline therapy	Asparaginase-containing pediatric or pediatric-inspired regimens	AYA and adult ALL populations

Drug, Administration & NDC Codes

The evidence provides HCPCS/J-code mappings for multiple infused or cellular ALL therapies and representative NDC information for selected oral and injectable agents. The document does not explicitly define pharmacy-benefit versus medical-benefit adjudication rules.

Logic

Ready | 8 sources

What this means

HCPCS-coded therapies can support medical-claim exposure identification, while oral kinase inhibitors and maintenance agents may require pharmacy-claim integration using NDCs. Mixed oral and infused product representation introduces routing and completeness challenges for line-of-therapy reconstruction.

Worth checking: Expert review should confirm whether alternate HCPCS descriptors or retired codes need harmonization across study years.

Sources

FDA NDC Directory (openFDA) CMS HCPCS Release Files NLM Clinical Tables (HCPCS) FDA Drug Labeling (openFDA)

Agent	HCPCS / J-code	NDC / labeler	Benefit	Note
Blinatumomab	J9039	Not supplied	Medical claim construct inferred from HCPCS coding	HCPCS description states injection, blinatumomab, 1 microgram
Inotuzumab ozogamicin	J9229	Not supplied	Medical claim construct inferred from HCPCS coding	HCPCS description states injection, inotuzumab ozogamicin, 0.1 mg
Rituximab	J9312	Biosimilars include Truxima, Ruxience, and Riabni	Medical claim construct inferred from HCPCS coding	FDA Purple Book identifies rituximab biosimilars
Dasatinib (SPRYCEL)	Not supplied	0003-0528; 0003-0524; 0003-0857 / E.R. Squibb & Sons, L.L.C.	Oral NDC-based product	Oral tablet product for Ph+ ALL context
Ponatinib hydrochloride (Iclusig)	Not supplied	63020-533-30; 63020-535-30; 63020-535-60; 63020-536-30 / Takeda Pharmaceuticals America, Inc.	Oral NDC-based product	NDA oral tablet products with multiple strengths
Clofarabine injection	Not supplied	43598-309-20 / Dr. Reddy's Laboratories Inc	Intravenous injection product	ANDA intravenous injection product for relapsed or refractory ALL after at least two prior regimens
Nelarabine (Arranon)	Not supplied	0078-0683-61; 66758-165-94 / Novartis Pharmaceuticals Corporation; Sandoz Inc	Intravenous injection product	Used in relapsed/refractory T-ALL/T-LBL contexts
Methotrexate sodium	J9250 and J9260	Multiple formulations and manufacturers identified	Both oral and injectable formulations identified	Potential same-drug different-intent ambiguity across maintenance and meningeal prophylaxis contexts

Exclusions & Ambiguity Rules

The supplied evidence identifies selected supportive-care examples and multiple ambiguity considerations but does not provide a comprehensive exclusion framework for ALL claims sequencing analyses. Same-drug different-intent ambiguity is specifically noted for methotrexate.

Logic

Ready | 9 sources |includes web evidence

The supplied evidence does not provide a comprehensive exclusion framework for supportive-care, prophylactic, rescue, adjunctive, transfusion-support, tumor-lysis, antiemetic, anti-infective, or non-t
Low-molecular-weight heparins at prophylactic doses are described as a first-line prophylactic anticoagulation strategy in ALL supportive care contexts.
LEUKINE is described as a leukocyte growth factor indicated to shorten neutrophil recovery time and reduce severe infections.
The evidence references transfusion-related endpoints including platelet and RBC transfusion independence.
The supplied evidence identifies oral therapies such as dasatinib and ponatinib and infused therapies such as BLINCYTO, BESPONSA, KYMRIAH, and TECARTUS but does not define pharmacy-benefit versus medi
Same-drug different-intent ambiguity may arise for methotrexate because both injectable and oral formulations are identified along with maintenance-regimen and meningeal leukemia prophylaxis or treatm

What this means

Supportive-care filtering and ambiguity resolution will require analyst-defined governance because the source material does not standardize exclusions or routing conventions. Methotrexate exposure classification may require indication-sensitive logic to distinguish maintenance therapy from prophylactic or other treatment contexts.

Worth checking: Expert review should focus on whether methotrexate prophylaxis exposures should be excluded from regimen-defining logic.

Sources

FDA NDC Directory (openFDA) FDA Drug Labeling (openFDA) DailyMed NLM Clinical Tables (HCPCS)

Treatment Journey States

The supplied documents describe ALL as a prolonged multiphase treatment journey with induction, consolidation, maintenance, remission surveillance, relapsed or refractory treatment, and possible HSCT or CAR-T pathways. Response states include CR, CRi, MRD positivity, MRD negativity, relapse, and transplant eligibility.

Journey

Ready | 6 sources |includes web evidence

Induction combination chemotherapy
Consolidation phase chemotherapy
Maintenance or continued therapy
CR or CRi assessment
MRD-positive or MRD-negative
Relapsed or refractory treatment
HSCT bridge or transplant
CAR-T pathway in relapsed disease

What this means

Claims-derived line-of-therapy reconstruction can follow transitions between induction, consolidation, maintenance, relapse treatment, HSCT, and CAR-T through encounter and infusion patterns. Laboratory-defined remission and MRD states are clinically central but are not directly observable in administrative claims.

Worth checking: Confirm whether CAR-T positioning applies only to relapsed or refractory B-cell ALL.

Sources

DailyMed National Cancer Institute (NCI) NLM Clinical Tables (LOINC) CIBMTR

Discontinuation & Adverse-Event Signals

Multiple ALL therapy classes include toxicity-driven interruption, discontinuation, or dose-modification signals. Key toxicities include CRS and ICANS with BLINCYTO, hepatotoxicity and VOD with BESPONSA, cardiomyopathy with anthracyclines, and severe toxicities with vincristine-based therapy.

Journey

Ready | 6 sources |includes web evidence

What this means

Treatment gaps, hospitalization, transfusions, dose reductions, and infusion interruptions may function as proxy indicators of discontinuation or toxicity-related modification in claims analyses. The supplied evidence does not define validated claims-based discontinuation thresholds or switching algorithms.

Worth checking: Verify whether dose-reduction percentages were regimen-specific or broadly generalized.

Sources

DailyMed FDA Drug Labeling (openFDA) National Cancer Institute (NCI) ASCO

Agent class	Signature adverse event	Effect on treatment
Bispecific CD19-directed CD3 T-cell engager (BLINCYTO)	Cytokine Release Syndrome (CRS)	Interrupt or discontinue BLINCYTO
Bispecific CD19-directed CD3 T-cell engager (BLINCYTO)	Neurological toxicities including ICANS	Interrupt or discontinue BLINCYTO
CD22-directed antibody-drug conjugate (BESPONSA)	Hepatotoxicity including VOD	Dosing interruption, dose reduction, or permanent discontinuation
Anthracycline therapy (doxorubicin-containing regimens)	Cardiomyopathy	Discontinue anthracycline therapy
Anthracycline therapy (doxorubicin-containing regimens)	Severe myelosuppression and infection	Hospitalization, transfusions, delayed cycles
Vincristine-based therapy	Severe toxicities	Dose reduction to 50% of normal dose
Multiagent chemotherapy regimens	Neutropenic fever or unresolved toxicities	Delayed cycles or dose modifications

Monitoring & Response Assessment

Treatment response assessment includes CR, CRi, bone marrow blast assessment, peripheral blood count recovery, and MRD-related milestones. Monitoring cadence is only partially described, with frequent follow-up exams and tests after therapy and no standardized claims-based cadence framework defined.

Journey

Ready | 7 sources |includes web evidence

What this means

Claims can identify biopsy encounters and follow-up utilization patterns, but remission status, MRD results, and marrow blast percentages remain laboratory-based concepts outside direct claims capture. Monitoring cadence definitions are incomplete for standardized line-of-therapy analytics.

Worth checking: Confirm that the monthly follow-up language applies broadly to adult ALL survivorship monitoring.

Sources

DailyMed NLM Clinical Tables (LOINC) National Cancer Institute (NCI) American Cancer Society

Assessment	Tool / criteria	Timing
Complete remission (CR)	< 5% blasts in bone marrow and absence of peripheral blood leukemic blasts	During response assessment
Complete remission with incomplete hematologic recovery (CRi)	Bone marrow remission with incomplete platelet and/or ANC recovery	During response assessment
MRD assessment	MRD negativity milestone; MRD greater than or equal to 0.1% referenced in indication	First or second complete remission
Bone marrow assessment	Bone marrow biopsy reporting and pathology assessment	During disease evaluation
Disease response documentation	Disease-specific laboratory results, cytogenetic and molecular markers, staging	At transplantation reporting and disease assessment
Follow-up monitoring	Blood tests, bone marrow exams, and other tests	Every month or so at first, then less often
Toxicity monitoring	Clinical examinations and symptom review	During and after treatment

Outcomes & Claims Observability

The supplied evidence describes downstream outcome states including complete remission, MRD negativity, relapse, post-transplant complications, hospitalization, survivorship, and death. Claims observability is strongest for hospitalization, transfusion, bone marrow biopsy encounters, treatment interruption, and transplant-related utilization.

Journey

Ready | 8 sources |includes web evidence

What this means

Administrative claims data are more reliable for identifying utilization-based journey events than clinical response states. Cohort definitions requiring CR, CRi, or MRD status would need linkage to laboratory, registry, or chart data.

Worth checking: Check whether home infusion observability differs by medical versus pharmacy benefit capture.

Sources

DailyMed FDA Drug Labeling (openFDA) NLM Clinical Tables (LOINC) National Cancer Institute (NCI)

Journey signal	Observable in claims	How
Hospitalization during induction or toxicity management	DIRECT SIGNAL	Inpatient hospitalization encounters
Transfusion requirement	DIRECT SIGNAL	Transfusion-related claims
Bone marrow biopsy encounter	DIRECT SIGNAL	Procedure or pathology-related claims
Treatment interruption or delayed cycle	PROXY SIGNAL	Treatment gaps or delayed infusion timing
Dose reduction	PROXY SIGNAL	Reduced administered dose intensity
MRD status	NOT OBSERVABLE	Laboratory-defined clinical concept without claims methodology
Complete remission status	NOT OBSERVABLE	Remission definitions depend on marrow and laboratory results
Home infusion and ambulatory monitoring	PROXY SIGNAL	Home infusion therapy and outpatient monitoring encounters

Unmet Needs & Evidence Gaps

The supplied evidence indicates that adult ALL treatment complexity, subgroup heterogeneity, and dependence on molecular and MRD testing create major limitations for standardized claims-based line-of-therapy construction. Explicit sequencing evidence is limited to isolated frontline-to-second-line asparaginase switching examples, including 35/154 (22.7%) patients switching from frontline pegaspargase/calaspargase pegol to recombinant Erwinia.

Celestra Synthesis

Ready | 5 sources |includes web evidence

What this means

Claims-only ALL analyses will require explicit assumptions for line transitions, remission, relapse, and discontinuation because clinically important disease and response variables depend on molecular and laboratory assessments. Cohort logic must preserve subgroup qualifiers such as Ph+ ALL and Ph- B-ALL to avoid inappropriate generalization.

Worth checking: Confirm whether frontline-to-second-line asparaginase switching should be treated as a true line advancement or toxicity-driven substitution.

Sources

NCI SEER PubMed Europe PMC ClinicalTrials.gov

Gap area	Description	Impact on modelling
Treatment sequencing standardization	Adult ALL treatment lacks a single standardized regimen approach because “The standard treatment for adults with ALL con	Regimen grouping and line attribution may vary across analyses because treatment sequences are heterogeneous and multi-s
Limited claims-based line definition evidence	The supplied evidence provides only isolated examples of claims-oriented sequencing definitions, including patients who	Claims-based line-of-therapy algorithms may require operational assumptions due to sparse published sequencing rules.
Population heterogeneity	Evidence distinguishes molecular and disease subgroups including “Ph+ ALL,” “Philadelphia (Ph) chromosome-negative B-cel	Subpopulation-specific evidence cannot be generalized across all ALL populations without preserving subgroup qualifiers.
Molecular subtype observability	Clinically relevant disease characterization includes “EP300::ZNF384,” “TCF3::ZNF384,” and kinase/RAS pathway mutations.	Administrative claims data may not capture the molecular features needed for clinically meaningful stratification.
Response and remission ascertainment	Key treatment states rely on specialized assessments including “bone marrow morphologic complete remission,” “flow cytom	Remission and MRD states may require proxy definitions because these assessments are not directly observable in claims.
Relapse characterization limitations	Outcomes literature reports that “nearly half of patients relapsed within 3 years,” but no standardized claims-based rel	Longitudinal relapse detection and post-relapse sequencing may be inconsistently defined across datasets.

Guideline, Label & Evidence Divergence

The supplied document contains limited direct evidence on guideline-label divergence in ALL, but identifies tensions between subgroup-specific approval statements, heterogeneous regimen practices, and sparse sequencing definitions. The evidence does not provide detailed NCCN-to-label comparisons or temporal FDA label evolution.

Celestra Synthesis

Ready | 3 sources |includes web evidence

What this means

The available evidence supports cautious interpretation of guideline and label applicability because subgroup restrictions and heterogeneous treatment practices are common in ALL. Claims-based sequencing frameworks should therefore include traceable assumptions and explicit subgroup handling.

Worth checking: Verify the exact frontline approval population associated with the blinatumomab statement before using it in downstream materials.

Sources

Europe PMC ClinicalTrials.gov Open Web (Supplementary)

Topic	Guideline says	Label / evidence says	Resolution
Frontline targeted therapy approval scope	NCCN-related commentary describes ALL treatment as complex and heterogeneous.	One source states that “Blinatumomab is currently the only targeted agent approved for frontline treatment,” but the sup	Preserve the exact subpopulation scope when interpreting frontline targeted therapy statements and avoid generalizing ac
Standardization of adult ALL regimens	NCCN-related commentary describes ALL treatment as “one of the most complex and difficult” hematologic malignancies.	The evidence states “there is no standard which drugs to give and how to combine them.”	Use transparent regimen grouping logic because no universal adult ALL sequencing standard was identified in the supplied
Claims-based sequencing transitions	No guideline-defined claims-based line-of-therapy algorithm was supplied.	Published evidence identified only isolated transitions such as switching from “frontline (1 L) pegaspargase (PEG)/calas	Document all sequencing assumptions explicitly when constructing retrospective treatment lines.
Subpopulation applicability	Several cited studies are restricted to “adults with Ph- B-ALL.”	The evidence also distinguishes “Ph+ ALL” and fusion-defined subtypes including “EP300::ZNF384” and “TCF3::ZNF384.”	Maintain subgroup-specific attribution because evidence and potential treatment approaches differ across molecularly def

Key Insights for Downstream Modelling

The supplied evidence highlights that ALL claims-based modelling is constrained by incomplete observability of molecular subtype, MRD status, remission assessment, and standardized relapse logic. Published sequencing evidence is limited and highly subgroup-specific.

Celestra Synthesis

Ready | 5 sources |includes web evidence

Claims-based ALL analyses may require proxy definitions for remission, relapse, treatment discontinuation, and maintenance because key clinical states depend on MRD testing, flow cytometry, RT-qPCR, a
Subgroup qualifiers such as “Ph- B-ALL,” “Ph+ ALL,” and fusion-defined populations including “EP300::ZNF384” and “TCF3::ZNF384” should be preserved throughout cohort construction and treatment sequenc
Adult ALL regimens involve “different combinations and ... several steps,” and the supplied evidence states that “there is no standard which drugs to give and how to combine them,” limiting standardiz
Published claims-oriented sequencing evidence is limited to isolated examples such as switching from frontline pegaspargase/calaspargase pegol to second-line recombinant Erwinia.
No validated claims-based relapse detection algorithm or maintenance therapy definition was identified in the supplied evidence.

What this means

Downstream modelling should emphasize transparent sequencing assumptions, subgroup preservation, and explicit handling of unobservable clinical states. Validation workflows should specifically review remission logic, molecular subgroup attribution, and line-transition traceability.

Worth checking: Check whether the intended modelling framework distinguishes therapy substitution from advancement to a new line of therapy.

Sources

NCI SEER PubMed Europe PMC ClinicalTrials.gov

Discovery phase (9 cards)

Reviewed at the gate

Epidemiology

Acute lymphocytic leukemia in the United States has a reported incidence rate of 1.9 per 100,000 men and women per year and a death rate of 0.4 per 100,000 men and women per year. SEER reported 126,118 people living with acute lymphocytic leukemia in 2023 and a 5-year relative survival of 73.2% during 2016–2022.

Clinical

Ready | 9 sources |includes web evidence

1.9 per 100,000 per year

Incidence rate

0.4 per 100,000 per year

Death rate

126,118

Estimated US prevalence

73.2%

5-year relative survival

<20 years

Most frequently diagnosed age group

2 to 5 years

Peak pediatric incidence age

What this means

Claims-based cohorting should distinguish pediatric, adolescent and young adult, and adult populations because disease incidence and outcomes differ by age setting. Subpopulation segmentation is also relevant for adult Philadelphia chromosome-negative B-cell ALL because outcome data were reported separately for this subgroup.

Worth checking: Check that prevalence year remains 2023 in the cited SEER extract.

Sources

Orphanet / Orphadata NCI SEER CDC / NCHS WHO Global Health Observatory

Patient Population & Segmentation

The supplied evidence segments ALL populations by age group, lineage, molecular subtype, MRD status, and risk category. B-cell lineage disease represented 79.3% of cases and T-cell lineage disease represented 20.7% in the cited immunophenotyping dataset.

Clinical

Ready | 7 sources |includes web evidence

What this means

Claims-based line-of-therapy analyses should preserve biologic and risk subgroup definitions, including B-cell versus T-cell lineage, Philadelphia chromosome status, MRD status, and age setting. These cohort-defining forks are directly linked to treatment selection and transplant consideration in the supplied evidence.

Worth checking: Expert review should confirm whether the lineage proportions are intended as representative or study-specific.

Sources

WHO National Cancer Institute (NCI) Orphanet / Orphadata ASH / Blood (American Society of Hematology)

Segment	Approximate share	Defining feature
Children and adolescents	Most common population	Most frequently diagnosed among people aged <20
Childhood ALL peak incidence	Not quantified	Peak incidence between 2 and 5 years of age
B-cell acute lymphoblastic leukemia (B-ALL)	79.3%	CD19, CD22, cytoplasmic CD79a markers
T-cell acute lymphoblastic leukemia (T-ALL)	20.7%	Cytoplasmic CD3 and CD5 markers
Philadelphia chromosome-negative B-cell ALL	Not quantified	Adult B-cell ALL molecular subgroup
ZNF384-rearranged B-cell ALL	Rare subtype	EP300::ZNF384 and TCF3::ZNF384 fusion partners
MRD-negative patients	Not quantified	Treatment segmentation by MRD status
Patients in MRD-positive CR1	Not quantified	Higher-risk treatment cohort

Disease Definition & Taxonomy

ALL is described as a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation. The supplied evidence classifies disease by lineage, molecular subgroup, and treatment-relevant biologic features.

Clinical

Ready | 9 sources |includes web evidence

What this means

Disease taxonomy in claims research should retain lineage, molecular subgroup, and MRD-based risk segmentation because these categories define treatment pathways and transplant eligibility. The evidence also supports separating adult Philadelphia chromosome-negative B-cell ALL from broader ALL populations.

Worth checking: Review whether ALL should be labeled as leukemia versus rare Non-Hodgkin lymphoma in downstream taxonomy standards.

Sources

Orphanet / Orphadata WHO National Cancer Institute (NCI) NCI SEER

Classification	Category	Note
Acute lymphoblastic leukemia	Rare Non-Hodgkin lymphoma	Malignant lymphoid proliferation affecting marrow and blood
B-cell acute lymphoblastic leukemia	Lineage subtype	Defined using CD19, CD22, cytoplasmic CD79a
T-cell acute lymphoblastic leukemia	Lineage subtype	Defined using cytoplasmic CD3 and CD5
Philadelphia chromosome-negative B-cell ALL	Molecular subgroup	Adult treatment-linked subgroup
ZNF384-rearranged B-cell ALL	Molecular subgroup	Includes EP300::ZNF384 and TCF3::ZNF384 fusions
MRD-positive CR1 disease	Risk subgroup	Used for treatment stratification
Higher-risk subsets	Risk category	May require allogeneic transplantation

Diagnostic Foundation

The supplied evidence describes a diagnostic workflow based on bone marrow assessment, morphology, cytochemical testing, immunophenotyping, cytogenetics, and lumbar puncture evaluation.

Clinical

Ready | 5 sources |includes web evidence

Bone marrow aspiration
Morphology assessment
Cytochemical analysis
Flow cytometric immunophenotyping
Lineage marker evaluation
Cytogenetics testing
Immunohistochemistry assessment
Lumbar puncture evaluation

What this means

Claims algorithms for incident ALL may need combinations of marrow procedures, flow cytometry, cytogenetic testing, and CNS-directed evaluation to improve diagnostic specificity. Lineage-defining immunophenotyping is central to distinguishing B-cell versus T-cell disease cohorts.

Worth checking: The sequence of diagnostic steps was inferred from the supplied workup descriptions rather than a formal guideline.

Sources

WHO Orphanet / Orphadata Europe PMC ASH / Blood (American Society of Hematology)

Natural History & Disease Journey

The supplied materials describe an ALL disease course involving diagnostic confirmation, lineage and molecular classification, MRD-based risk assessment, frontline treatment selection, and escalation for higher-risk or suboptimal responders.

Clinical

Ready | 8 sources |includes web evidence

Initial symptom presentation
Bone marrow confirmation
Immunophenotypic lineage assignment
Molecular subgroup classification
MRD status assessment
Frontline treatment selection
Response-based risk stratification
Transplant consideration for high-risk

What this means

Claims-based line-of-therapy construction should incorporate transitions driven by MRD status, biologic subgrouping, and response assessment because these factors determine escalation and transplant pathways. Age setting and molecular classification also define distinct treatment journeys.

Worth checking: Relapse sequencing details were limited in the supplied evidence.

Sources

Orphanet / Orphadata National Cancer Institute (NCI) NCI SEER CDC / NCHS

Treatment Landscape

The supplied evidence describes ALL treatment as stratified by Philadelphia chromosome/BCR::ABL1 status, lineage subtype, age group, and MRD context across induction, consolidation, maintenance, transplant, and relapsed/refractory settings. Therapeutic modalities identified include multiagent chemotherapy, tyrosine kinase inhibitors for Ph+ ALL, immunotherapy, CAR-T therapy, transplant approaches, and lineage-specific agents.

Treatment

Ready | 9 sources |includes web evidence

What this means

Claims-based line-of-therapy construction should segment patients by Ph/BCR::ABL1 status, lineage subtype, age group, MRD context, relapsed/refractory status, CAR-T exposure, and transplant exposure. The evidence supports mapping treatment journeys across induction, consolidation, maintenance, and reinduction phases.

Worth checking: Confirm whether AYA-focused ASH recommendations should be operationalized separately from adult NCCN pathways.

Sources

FDA Drug Labeling (openFDA) ESMO FDA National Cancer Institute (NCI)

Therapy class	Examples	Key populations / role
Multiagent chemotherapy	Prednisone, vincristine, and an anthracycline	Adult ALL remission induction
Pediatric-inspired asparaginase-containing regimens	Asparaginase-containing regimens	Frontline therapy for adolescents and young adults (AYAs) with ALL
Tyrosine kinase inhibitors (TKIs)	Imatinib, dasatinib, ponatinib	Philadelphia chromosome-positive (Ph+) ALL
Immunotherapy / targeted reinduction	Blinatumomab and/or inotuzumab	Relapsed/refractory AYA ALL reinduction
CAR-T cellular therapy	TECARTUS (brexucabtagene autoleucel)	Adult relapsed or refractory B-cell precursor ALL
Lineage-specific therapy	Nelarabine	Relapsed/refractory T-ALL/T-LBL after at least two chemotherapy regimens
Transplant consolidation	Allogeneic hematopoietic stem cell transplantation (HSCT)	Higher-risk subsets or patients with suboptimal responses; consolidation/transplant decision point

Guideline / Standard of Care

The supplied evidence identifies NCCN adult ALL guidelines Version 2.2024, NCCN Pediatric ALL guideline Version 2.2025, and ASH 2026 ALL guidelines as major U.S. standards governing treatment selection. Pathways branch by Ph/BCR::ABL1 status, lineage, age group, MRD status, and relapsed/refractory setting.

Treatment

Ready | 9 sources |includes web evidence

What this means

Guideline-driven cohort logic should incorporate biomarker testing and MRD assessment at diagnosis and during treatment transitions because treatment branching depends on these factors. Separate cohort definitions may be required for pediatric, AYA, and adult populations and for Ph+ versus Ph-negative disease.

Worth checking: Check whether the cited ASH 2026 recommendations are intended only for AYAs and should not be generalized to all adults with ALL.

Sources

ESMO FDA Drug Labeling (openFDA) FDA National Cancer Institute (NCI)

Guideline / body	Population	Recommended approach
NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia Version 2.2024	Adults with Ph-positive and Ph-negative ALL	Treatment strategies stratified by Philadelphia chromosome status, age, MRD assessment, and supportive care consideratio
NCCN Pediatric Acute Lymphoblastic Leukemia guideline Version 2.2025	Pediatric BCR::ABL1-positive and BCR::ABL1-negative B-cell lineage, T-cell lineage, and infant ALL	Risk assessment and stratification of risk-adapted therapy
American Society of Hematology 2026 frontline management guideline	Adolescents and young adults (AYAs) with B-ALL/T-ALL or T-LBL/LLy receiving frontline therapy	Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with traditional adult
American Society of Hematology 2026 relapsed/refractory guideline	AYAs with relapsed/refractory ALL	Blinatumomab and/or inotuzumab over chemotherapy for reinduction
NCCN and ASH pathway structure	ALL across treatment phases	Pretreatment, induction, consolidation, maintenance therapy, and allogeneic HSCT decision points guided by biomarker and

Approved Therapy & Label Intelligence

The supplied evidence identifies FDA-approved therapies for ALL spanning Ph+ disease, relapsed/refractory T-ALL/T-LBL, pediatric relapsed/refractory ALL, maintenance therapy, and adult relapsed/refractory B-cell precursor ALL. Recent regulatory activity includes a 2024 FDA accelerated approval for ponatinib with chemotherapy in newly diagnosed adult Ph+ ALL.

Treatment

Ready | 7 sources |includes web evidence

What this means

Approved therapy mapping supports claims segmentation by biomarker-defined disease, age group, lineage, and treatment setting. Frontline versus relapsed/refractory distinctions are essential because several approvals are limited to specific lines and subpopulations.

Worth checking: Verify whether unavailable approval dates for TECARTUS should be supplemented from an external FDA source.

Sources

FDA Drug Labeling (openFDA) FDA Drugs@FDA (openFDA) ESMO ClinicalTrials.gov

Therapy	Indication / population	Setting	Approval	Recent label change
Ponatinib (ICLUSIG)	Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with chemoth	Frontline newly diagnosed adult Ph+ ALL	FDA accelerated approval 2024-03-19	2025-10-10 ICLUSIG SUPPL 38 efficacy supplement; specific ALL scope not provided
Dasatinib (SPRYCEL)	Adults with Ph+ ALL with resistance or intolerance to prior therapy; pediatric patients 1 year of age and older with new	Relapsed/refractory adult Ph+ ALL and frontline pediatric Ph+ ALL	Initial U.S. Approval: 2006	2024-07-31 SPRYCEL SUPPL 28 labeling action; specific ALL scope not provided
Imatinib mesylate (Gleevec/imatinib)	Adult relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukemia and pediatric newly diagnosed Ph	Relapsed/refractory adult Ph+ ALL and frontline pediatric Ph+ ALL	Initial U.S. Approval: 2001	Multiple FDA supplement approval dates including SUPPL 63 AP 2024-03-01; ALL scope not specified
Nelarabine (ARRANON)	Adult and pediatric patients age 1 year and older with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblas	Relapsed/refractory T-ALL/T-LBL after at least two regimens	Initial U.S. Approval: 2005	2025-03-11 ARRANON SUPPL 14 labeling action; specific ALL scope not provided
Clofarabine injection	Pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least two prior regimens	Pediatric relapsed/refractory ALL	Initial U.S. Approval: 2004	No recent label change identified in supplied evidence
Methotrexate Injection	Adult and pediatric ALL as part of a combination chemotherapy regimen or maintenance regimen	Combination chemotherapy and maintenance settings	Initial U.S. Approval: 1953	No recent label change identified in supplied evidence
TECARTUS (brexucabtagene autoleucel)	Adult relapsed or refractory B-cell precursor ALL	Relapsed/refractory adult B-cell precursor ALL	Approved; approval date not provided in supplied evidence	No recent label change identified in supplied evidence

Key Clinical & Treatment Insights

The discovery phase established that Acute Lymphoblastic Leukemia treatment pathways, outcomes, and regulatory positioning are highly stratified by age group, lineage subtype, Philadelphia chromosome/BCR::ABL1 status, molecular subgroup, MRD context, and relapsed/refractory status.

Celestra Synthesis

Ready | 16 sources

The supplied evidence segments ALL populations by age group, lineage, molecular subtype, MRD status, and risk category, with B-cell lineage disease representing 79.3% of cases and T-cell lineage disea
Diagnostic classification frameworks rely on bone marrow assessment, morphology, cytochemical testing, immunophenotyping, cytogenetics, and lumbar puncture evaluation, with lineage assignment supporte
Treatment selection pathways are stratified across induction, consolidation, maintenance, transplant, and relapsed/refractory settings by Philadelphia chromosome/BCR::ABL1 status, lineage subtype, age
The supplied evidence identifies molecular subgrouping that includes Philadelphia chromosome-negative B-cell ALL and ZNF384-rearranged B-ALL with EP300::ZNF384 and TCF3::ZNF384 fusion partners.
NCCN adult ALL Version 2.2024, NCCN Pediatric ALL Version 2.2025, and ASH 2026 guidelines govern treatment selection using branching logic based on Ph/BCR::ABL1 status, lineage, age group, MRD status,
FDA-approved therapies identified in the supplied evidence span specific ALL subpopulations and settings including Ph+ disease, relapsed/refractory T-ALL/T-LBL, pediatric relapsed/refractory ALL, main

What this means

Downstream modelling should preserve ALL subpopulation stratification variables and setting-specific treatment branches because diagnostic classification, guideline pathways, and approved therapies are differentiated by lineage, molecular status, age group, MRD context, and relapsed/refractory statu

Sources

Orphanet / Orphadata NCI SEER CDC / NCHS WHO Global Health Observatory

Back to the current step Source conflicts

All findings

Mapping & Synthesis phase (15 cards)

Discovery phase (9 cards)

No insights match those filters